|Day Low/High||44.12 / 44.67|
|52 Wk Low/High||37.43 / 45.62|
SNY, RYN, I, SIG and K all recently were downgraded by TheStreet's Quant Ratings.
* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DHX, EWBC, KE, MSON, OMN, RDWR, RNR, SEE Downgrades: AR, FTAI, K, RYN, SNY, TWO, VNDA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
- First medicine approved in the U.S. specifically for the treatment of aTTP, a rare blood-clotting disorder
- The 0.5 mL dose is now approved for use in children 6 months through 35 months of age
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
* First and only vaccine approved in the U.S. for repeat vaccination 8 years or more after the first vaccination to help protect against tetanus, diphtheria and pertussis, offering flexibility for health care providers to help manage their immunization schedules(2)
PARIS, Dec. 18, 2018 /PRNewswire/ -- Sanofi today announced that it will be transferring the listing of its American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market (Nasdaq) effective December 31, 2018,...
Warren Buffett's big buys of Oracle and JPMorgan have those stocks jumping Thursday.
* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL
* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
PARIS , Oct. 31, 2018 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q3 2018 Change Change at CER 9M 2018 Change Change at CER IFRS net sales reported €9,392m +3.
-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype
LAVAL, QC, Oct. 17, 2018 /CNW Telbec/ - Sanofi Canada is on a mission to raise awareness and money to help people living with diabetes, one of the leading causes of death and disability in Canada.
- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery
When Out-of-Pockets get too high, there are many programs to help, whether or not you have insurance
Influenza has a significant human and economic impact due to the burden of illness and high number of hospitalizations.
* Libtayo is the third anti-PD-1 approved in the U.S.
Nvidia, nvidia, NVIDIA. In non-Nvidia news, the market faces some serious threats in the back half of 2018. And hey, about Elon Musk's latest interview ...
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CFBK, CLDT, SNY, VET Downgrades: ADNT, AOI, BVN Initiations: AMMA Read on to get TheStreet Quant Ratings' detailed report:
Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.
While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.